Log In
Print
BCIQ
Print
Print this Print this
 

PT003

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionCombination of glycopyrrolate (PT001), a long-acting muscarinic antagonist (LAMA), and formoterol fumarate (PT005), a long-acting adrenergic receptor beta 2 agonist (LABA), delivered via a hydrofluoroalkane metered-dose inhaler
Molecular Target Adrenergic receptor beta 2 (ADRB2) ; Muscarinic receptor
Mechanism of ActionAdrenergic receptor beta 2 (ADRB2) agonist
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentPhase III
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat chronic obstructive pulmonary disease (COPD); Treat moderate to very severe chronic obstructive pulmonary disease (COPD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,150.0M

$560.0M

$590.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today